Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients

Abstract EN

Introduction.

In this study, we aimed to demonstrate the correlation of FGF-23 levels with bone-mineral metabolism, anemia, and the treatment in dialysis patients.

Methods.

Eighty-nine patients with similar age, gender, dialysis duration, and dialysis adequacy who were receiving hemodialysis replacement therapy for at least 6 months were included in the study.

Serum iron, iron binding capacity, ferritin, hemoglobin (Hb), hematocrit (Htc), calcium (Ca), phosphorus (P), intact parathormone (iPTH), and FGF-23 levels were studied.

In addition, active vitamin D and phosphate binders calcimimetic therapies that patients have received in the last 6 months were recorded.

Results.

It was determined that there was a positive correlation between serum FGF-23 values and PTH values (P<0,01) and Ca*P values (P<0,01).

A positive correlation was found between serum FGF-23 values and Ca values at a rate of 24,6% (P<0,05) and between P values at a rate of 59,1% (P<0,01).

A positive correlation was determined between serum FGF-23 values and hemoglobin (Hb) values (P<0,05) and hematocrit (Htc) values (P<0,05).

In multivariate analysis, no significant correlation was found between serum FGF-23 levels and Hb and Htc.

Conclusion.

The effects of high serum FGF-23 levels on different parameters may be correlated with the development of refractory secondary hyperparathyroidism.